Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

Paused · Not applicable

Conditions studied: Frail Elderly Syndrome, Aging, Degenerative Disease

In brief

With increasing age and health issues associated with aging, many systemic cellular and structural changes are known to occur. The intent of this trial is to determine the safety and efficacy of delivery of autologous cellular stromal vascular fraction (cSVF) to improve the quality of life and functional health. Isolation and concentration of cSVF will be documented. To acquire autologous cSVF, a 10+ teaspoon volume of subdermal adipose (fat) tissue and stroma is removed from the trunk or upper thigh area. Using a closed system with enzymatic digestion to isolate and concentrate these cells, is followed with returning these cSVF elements only via 500 cc Normal Saline delivered via peripheral vein (IV). Documentation of cellular numbers and flow cytometer viability testing is to be correlated with clinical outcomes as reported by patients and standardized Quality of Life (QoL) form tracking

Key facts

Study ID: NCT03514537
Run by: Healeon Medical Inc
People needed: 200
Starts: 2018-03-15
Expected to finish: 2028-01-15
Last updated by the study team: 2025-09-12

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Be >40 and <90 years of age and willing and able to provide written informed consent
Those aging and frail patients who have noted compromise to activities or work requirements due to increasing age
Ability to execute a 6 minute walk test distance of >200 meters and <1000 meters
Loss of energy and exercise tolerance over 6 month period minimum
Current clinical history of malignancy within 3 years, except for curable skin lesions including basal cell carcinoma, or squamous cell carcinoma
Must have the ability to provide Informed Consent

You may not qualify if…

Medical conditions which prevent the ability of assessment of walk distance testing criteria
Have disabling neurodegenerative disorder which would impede interpretation of outcomes
Have a score of <24 on the Mini Mental State Examination (MMSE)
History of malignancy within 2 years (excluding curative skin lesion of basal cell carcinoma, melanoma-in-situ, or cervical carcinoma
Have clinically important abnormal screening laboratory values, including, but not limited to: Hemoglobin <10 g/dL; White blood cell count (WBC) <2500/mL; Platelet count microliters <100000/uL(microliters); Genetic Coagulopathy history
Uncontrollable hypertension
Systemic disorders that preclude completion of the testing or out of medical management control in the opinion of the PIs or Primary Care Provider
Expected lifespan of less that 6 months
Current drug abuse history < 6 months
Alcohol abuse within 6 months of enrollment
Serious or life threatening co-morbidities that in the opinion of investigators, may compromise the safety or compliance with the study guidelines and tracking.

Where it is running

Fanny Island Campus Medical Building — Colchester, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.